Use of Inhibitors of the Degradation of P27, in Particular Argyrin and Derivatives Thereof, for the Treatment of Proliferative Diseases
AssigneesHelmholtz-Zentrum FüR Infektionsforschung GmbH, Medizinische Hochschule Hannover
InventorsNisar Malek, Florenz Sasse, Irina Nickeleit, Ronald Frank, Bettina Hinkelmann, Heinrich Steinmetz
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular Argyrin and derivatives thereof, preferably Argyrin A, for the treatment of proliferative diseases, such as cancer, as well as the derivatization of said macrocycles.
Claims23
A method of treating a proliferative disorder in a subject in need of such treatment, wherein said method comprising administering to the subject an effective amount of a compound of the formula I
- wherein
- R1 and R2 independently are hydrogen, C1-C4 alkyl which is unsubstituted or substituted by OH, or C1-C4 alkoxy;
- R3 is hydrogen, C1-C8 alkyl which is unsubstituted or substituted by OH or OR, wherein R is selected from hydrogen, C1-C4 alkyl, aryl or acetyl,
- R4 is hydrogen, halogen, C1-C4 alkyl which is unsubstituted or substituted by OH, or C1-C4 alkoxy;
- R5 is hydrogen or halogen;
- R6 is hydrogen or C1-C4 alkyl;
- and
- X is C═CH2 or CHR7 wherein R7 is C1-C4 alkyl which is unsubstituted or substituted by —S—C1-C4 alkyl, and pharmaceutically acceptable salts thereof.
A method for screening a compound for the ability to inhibit the degradation of p27, comprising
- contacting a cell with a compound suspected to inhibit the degradation of p27;
- assaying the contents of the cell to determine the amount and/or biological activity of p27 and/or the cell cycle status;
- and
- comparing the determined amount and/or biological activity of p27 or the cell cycle status with the amount and/or biological activity of p27 or the cell cycle status as found without the compound,
- wherein a change of said amount and/or biological activity of p27 or the cell cycle status is indicative for a compound that inhibits the degradation of p27.
18-22. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.